omeprazole has been researched along with Indigestion in 302 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 9.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
| "To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia." | 9.69 | Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial. ( Angsusing, J; Buamahakul, T; Chumsri, C; Khamsai, S; Khongkha, W; Kongkam, P; Kosarussawadee, P; Lopimpisuth, C; Phisalprapa, P; Phutrakool, P; Pongpirul, K; Poonniam, P; Sawanyawisuth, K; Siwamogsatham, S; Sura, T; Teerachaisakul, M; Wanaratna, K, 2023) |
| "To assess the impact of prophylactic omeprazole with background dual anti-platelet therapy on patient-reported symptoms of dyspepsia compared to placebo." | 9.20 | The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; McIntosh, AI; Schnitzer, TJ; Vardi, M, 2015) |
| "Patients identified as having acid-related dyspepsia more often developed epigastric pain following acid stimulation during placebo and not during omeprazole treatment." | 9.13 | Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model. ( Bytzer, P; Madsen, LG, 2008) |
| "One hundred and nineteen patients with functional dyspepsia completed a 12-day, double-blind random-starting-day trial with an initial placebo run-in followed by switch to omeprazole on a randomized and blinded day (between days 5 and 9) with active treatment continuing for the rest of the trial." | 9.11 | Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design. ( Bytzer, P; Madsen, LG, 2004) |
| "To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients." | 9.10 | Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. ( Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2002) |
| "To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia." | 9.10 | Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. ( Balzano, A; de Nucci, C; Manes, G; Menchise, A, 2003) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 9.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "The aim of this study was to compare the effect of a combination of lansoprazole, clarithromycin, and amoxicillin (LCA) versus placebo on the severity of symptoms in functional dyspepsia patients who were positive for Helicobacter pylori (H." | 9.10 | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. ( Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S, 2003) |
| "In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0." | 9.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 9.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| " pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 9.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
| "The effect of omeprazole therapy in dyspepsia is unpredictable." | 9.09 | Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial. ( Christensen, E; Meineche-Schmidt, V, 2000) |
| "A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group)." | 9.09 | Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia. ( Chuang, CH; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b." | 9.09 | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F, 2001) |
| "Patients with a history of dyspepsia or uncomplicated peptic ulcer disease and with a need for continuous NSAID treatment were randomized to receive either 20 mg omeprazole once daily or placebo." | 9.08 | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. ( Anker-Hansen, O; Carling, L; Ekström, P; Lundegårdh, G; Thorhallsson, E; Unge, P; Wetterhus, S; Wingren, PE, 1996) |
| "To examine dyspepsia symptom relief over 16 weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid-alginate followed by H2-antagonist." | 9.08 | The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. ( Evans, WM; Mason, I; Millar, LJ; Sheikh, RR; Taylor, MD; Todd, PL; Turbitt, ML, 1998) |
| "Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg, 10 mg or identical placebo, for 4 weeks." | 9.08 | Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). ( Duckworth, M; Kordecki, H; Meineche-Schmidt, V; Pap, A; Paré, P; Räisänen, P; Schmid, V; Talley, NJ, 1998) |
| "Treatment with omeprazole provides superior symptom relief compared to ranitidine, cisapride, and placebo in the treatment of H." | 6.71 | A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Lee, J; Sinclair, P; Smyth, S; Thomson, A; Veldhuyzen van Zanten, SJ, 2005) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | 6.69 | One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 5.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
| "To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia." | 5.69 | Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial. ( Angsusing, J; Buamahakul, T; Chumsri, C; Khamsai, S; Khongkha, W; Kongkam, P; Kosarussawadee, P; Lopimpisuth, C; Phisalprapa, P; Phutrakool, P; Pongpirul, K; Poonniam, P; Sawanyawisuth, K; Siwamogsatham, S; Sura, T; Teerachaisakul, M; Wanaratna, K, 2023) |
| "Acute interstitial nephritis is an uncommon but important cause of acute renal failure." | 5.33 | Rabeprazole-induced acute interstitial nephritis. ( Coleman, PL; Geevasinga, N; Roger, SD, 2005) |
| "When omeprazole was re-started she developed fever and acute renal failure, which again settled quickly on discontinuation of omeprazole." | 5.30 | Pyrexia, anaemia and acute renal failure secondary to omeprazole. ( Arnold, IR; Ferner, RE; Landray, MJ; Ringrose, T, 1998) |
| "To assess the impact of prophylactic omeprazole with background dual anti-platelet therapy on patient-reported symptoms of dyspepsia compared to placebo." | 5.20 | The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; McIntosh, AI; Schnitzer, TJ; Vardi, M, 2015) |
| "Helicobacter pylori -positive adult patients with functional dyspepsia meeting the Rome III International Consensus criteria were randomly assigned to receive omeprazole, amoxicillin trihydrate, and clarithromycin, or omeprazole plus placebo for 10 days." | 5.15 | Helicobacter pylori eradication in functional dyspepsia: HEROES trial. ( Berwanger, O; Birkhan, OA; Bressel, M; Colombo, Bda S; Dahmer, FD; De Bona, LR; Edelweiss, MI; Folador, L; Francesconi, CF; Grando, E; Guerrieri, PP; Heck, R; Hocevar de Moura, B; Katz, N; Lunkes, RP; Marini, SS; Mazzoleni, F; Mazzoleni, LE; Milbradt, TC; Molina, CG; Prolla, JC; Rauber, J; Renck, LB; Sander, GB; Spindler, BM; Uchoa, DM; Von Reisswitz, PS, 2011) |
| "Patients identified as having acid-related dyspepsia more often developed epigastric pain following acid stimulation during placebo and not during omeprazole treatment." | 5.13 | Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model. ( Bytzer, P; Madsen, LG, 2008) |
| "Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo." | 5.12 | Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. ( Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC, 2006) |
| "Adult Helicobacter pylori-positive patients by 13C-urea breath test with uninvestigated dyspepsia symptoms were randomized to 1-week eradication treatment with omeprazole, metronidazole and clarithromycin (OMC) vs." | 5.11 | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Grace, E; Lee, J; Sinclair, P; Thomson, AB; Veldhuyzen Van Zanten, SJ, 2004) |
| "One hundred and nineteen patients with functional dyspepsia completed a 12-day, double-blind random-starting-day trial with an initial placebo run-in followed by switch to omeprazole on a randomized and blinded day (between days 5 and 9) with active treatment continuing for the rest of the trial." | 5.11 | Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design. ( Bytzer, P; Madsen, LG, 2004) |
| "Symptoms described with the words 'burning' or 'sour' and patients with reflux-like dyspepsia demonstrated high response to omeprazole treatment, whereas patients with abdominal pain or ulcer-like dyspepsia responded unpredictably to omeprazole." | 5.11 | Classification of dyspepsia and response to treatment with proton-pump inhibitors. ( Meineche-Schmidt, V, 2004) |
| "Heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres were randomized to one of two active treatment strategies: omeprazole 20 mg daily (proton pump inhibitor-start) or ranitidine 150 mg bid (H2-receptor antagonist-start) for the first 4-8 weeks, stepping up to omeprazole 40 or 20 mg daily, respectively, for 4-8 weeks for persistent symptoms." | 5.11 | Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Sinclair, P; Smyth, S; Thomson, AB; Veldhuyzen van Zanten, SJ; White, RJ, 2005) |
| " pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b." | 5.11 | Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. ( Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z, 2004) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients." | 5.10 | Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. ( Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2002) |
| " pylori positive patients with non-ulcer dyspepsia were randomised to one of the following four treatment groups: omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA); omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM)." | 5.10 | The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. ( Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M, 2002) |
| "We conducted a double blind, randomized, placebo-controlled trial in which patients with uninvestigated dyspepsia were randomized to a 6-wk course of omeprazole 20 mg p." | 5.10 | A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. ( Ambriz, E; Huang, I; Menke, T; Rabeneck, L; Souchek, J; Wray, N; Wristers, K, 2002) |
| "The study was a secondary analysis of data obtained from a double-blind, randomized placebo-controlled trial, evaluating a 6-week course of omeprazole versus placebo in 140 patients with uninvestigated dyspepsia who were followed for up to 1 year." | 5.10 | Impact of upper endoscopy on satisfaction in patients with previously uninvestigated dyspepsia. ( Ambriz, E; Rabeneck, L; Souchek, J; Wristers, K, 2003) |
| " pylori-positive patients with non-ulcer dyspepsia received 1-week omeprazole-based triple therapy, or omeprazole plus placebos." | 5.10 | Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia. ( Blum, AL; Bolling-Sternevald, E; Mitchell, HM; O'Morain, CA; Stolte, M; Talley, NJ; Xia, HH, 2003) |
| "To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia." | 5.10 | Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. ( Balzano, A; de Nucci, C; Manes, G; Menchise, A, 2003) |
| "Data were pooled on patients (n = 826) with a diagnosis of functional dyspepsia from two placebo-controlled trials who were treated with omeprazole, 10 or 20 mg once daily, for 4 weeks." | 5.10 | Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? ( Bolling-Sternevald, E; Glise, H; Junghard, O; Lauritsen, K; Talley, NJ, 2003) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 5.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "Eight hundred patients with functional dyspepsia were randomized to receive double-blind treatment with twice-daily 30 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days (L30AC), twice-daily 15 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days (L15AC), or once-daily 15 mg lansoprazole for 14 days (LP)." | 5.10 | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. ( Demleitner, K; Fischbach, W; Fuchs, W; Layer, P; Leodolter, A; Malfertheiner, P; MOssner, J; Stolte, M, 2003) |
| "The aim of this study was to compare the effect of a combination of lansoprazole, clarithromycin, and amoxicillin (LCA) versus placebo on the severity of symptoms in functional dyspepsia patients who were positive for Helicobacter pylori (H." | 5.10 | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. ( Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S, 2003) |
| "To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers." | 5.10 | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. ( Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM, 2003) |
| "In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg)." | 5.10 | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. ( Ahn, DS; Choi, IJ; Choi, KW; Chung, IS; Chung, JM; Hong, WS; Jung, HC; Kim, JH; Lee, SI; Rew, JS; Rhee, JC; Yang, US, 2002) |
| "In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0." | 5.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
| "Helicobacter pylori-positive patients (224) with peptic ulcer disease or non-ulcer dyspepsia were randomized to receive one of three different omeprazole or lansoprazole-amoxycillin-clarithromycin (PPI/AC) regimens for 7 days: (1) OAC 20 regimen (n = 76), omeprazole (OPZ) 20 mg daily, amoxycillin (AMOX) 500 mg t." | 5.09 | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. ( Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S, 1999) |
| " pylori-positive patients with endoscopically defined peptic ulcer [DU (n = 65), GU (n = 12)] or non-ulcer dyspepsia (NUD, n = 43) were randomized to receive a 1-week course of twice daily omeprazole 20 mg, clarithromycin 250 mg and either metronidazole 400 mg (OCM) or tinidazole 500 mg (OCT) in a double-blind fashion." | 5.09 | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. ( Goddard, AF; Lawes, S; Logan, RP; Spiller, RC, 1999) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 5.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| "Patients with functional dyspepsia from Denmark, France, Germany, The Netherlands, Hungary, and Poland (n = 567 (215 men), 18-80 years old) were followed up for 3 months after a 4-week treatment trial with omeprazole (20 mg or 10 mg) or placebo." | 5.09 | Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. ( Bolling-Sternevald, E; Kordecki, H; Meineche-Schmidt, V; Ohlsson, L; Pap, A; Schmid, V; Talley, NJ; Wahlqvist, P; Wiklund, I, 1999) |
| " pylori-infected patients with nonulcer dyspepsia to receive twice-daily treatment with 20 mg of omeprazole, 1000 mg of amoxicillin, and 500 mg of clarithromycin for 14 days and 167 such patients to receive identical-appearing placebos; all patients were then followed through regular visits for 12 months." | 5.09 | Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. ( Ballard, ED; Fennerty, MB; Talley, NJ; Vakil, N, 1999) |
| " pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 5.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
| "After a complete diagnostic workup, 792 patients with functional dyspepsia unresponsive to one week of low dose antacid treatment were randomised to two weeks of treatment with placebo, ranitidine 150 mg, omeprazole 10 mg, or omeprazole 20 mg daily." | 5.09 | Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. ( Arnold, R; Blum, AL; Fischer, M; Koelz, HR; Stolte, M, 2000) |
| "The effect of omeprazole therapy in dyspepsia is unpredictable." | 5.09 | Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial. ( Christensen, E; Meineche-Schmidt, V, 2000) |
| " pylori who had functional dyspepsia were randomly assigned to 7 days of treatment with a lansoprazole-based triple therapy or placebo and then followed for 1 year." | 5.09 | Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. ( Chan, HH; Chen, W; Cheng, JS; Chien, EJ; Hsu, PI; Hsu, PN; Ku, MK; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Peng, NJ; Tseng, HH, 2001) |
| "A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group)." | 5.09 | Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia. ( Chuang, CH; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB, 2001) |
| "Non-ulcer dyspepsia patients (n=199), with a normal upper endoscopy and a positive (13)C-urea breath test (UBT) were randomly assigned to either pantoprazole, clarithromycin and metronidazole (PCM) or pantoprazole, clarithromycin and eicosapen (PCE) for 7 days." | 5.09 | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. ( Drewe, J; Geiser, HR; Meier, R; Wettstein, A, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " Ulcer-like dyspepsia seemed to benefit from omeprazole." | 5.09 | A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. ( Buskens, E; de Wit, NJ; Lewin van den Broek, NT; Numans, ME; Smout, AJ; Verheij, TJ, 2001) |
| "Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b." | 5.09 | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F, 2001) |
| "In functional dyspepsia, pantoprazole influenced the acid-induced duodenogastric feedback mechanism, but not the impaired duodenal motor response." | 5.09 | Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia. ( Samsom, M; Schwartz, MP; Smout, AJ; Van Berge Henegouwen, GP, 2001) |
| "pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd." | 5.08 | [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995) |
| " pylori infection and peptic ulcer disease (n = 64) or functional dyspepsia (n = 16), with similar demographic and clinical characteristics, were treated for 1 week with either omeprazole 20 mg once in the morning and clarithromycin 250 mg and metronidazole 400 mg twice daily (OCM; n = 40) or with omeprazole 20 mg once in the morning and clarithromycin 250 mg and tetracycline 500 mg twice daily (OCT; n = 40)." | 5.08 | One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Rühl, GH; Sollböhmer, M; Stolte, M; Tillenburg, B, 1995) |
| "We report the results of seven therapeutic trials combining omeprazole, clarithromycin, amoxycillin, colloidal bismuth subcitrate and tinidazole in 198 patients (peptic ulcer disease/non-ulcerative dyspepsia, 137/61) to eradicate H." | 5.08 | Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. ( Buset, M; De Koster, E; Deltenre, M; Jonas, C; Otero, J; van Gossum, M, 1995) |
| " Those patients with active duodenal ulcers present at endoscopy were given omeprazole 20 mg nocte for a further 21 days." | 5.08 | A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. ( Broadbent, A; Chambers, S; Gould, SR; Mistry, R; Ranganath, L; Weldon, MJ, 1996) |
| "Patients with a history of dyspepsia or uncomplicated peptic ulcer disease and with a need for continuous NSAID treatment were randomized to receive either 20 mg omeprazole once daily or placebo." | 5.08 | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. ( Anker-Hansen, O; Carling, L; Ekström, P; Lundegårdh, G; Thorhallsson, E; Unge, P; Wetterhus, S; Wingren, PE, 1996) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "In a prospective study, 113 patients with peptic ulcer (n = 36) or non-ulcer dyspepsia (n = 77) were randomized to receive 1-wk treatment, composed of omeprazole 20 mg b." | 5.08 | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. ( Attili, AF; Diana, F; Pugliano, F; Rinaldi, V; Zullo, A, 1997) |
| "To examine dyspepsia symptom relief over 16 weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid-alginate followed by H2-antagonist." | 5.08 | The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. ( Evans, WM; Mason, I; Millar, LJ; Sheikh, RR; Taylor, MD; Todd, PL; Turbitt, ML, 1998) |
| "In an open study 66 consecutive infected patients with ulcer disease or non-ulcer dyspepsia were treated with 4-day quadruple therapy after 3 days of lansoprazole pretreatment." | 5.08 | Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. ( de Boer, WA; Schneeberger, PM; van Etten, RJ, 1998) |
| "In order to explore the optimal regimens for the eradication of Helicobacter pylori (Hp), eighty-eight patients with duodenal ulcer (DU) or non-ulcer dyspepsia and Hp infection, defined by culture and histology, received the one-week triple therapy with clarithromycin (Cla), furazolidone (Fur) plus lansoprazole (Lan) or colloidal bismuth subcitrate (CBS)." | 5.08 | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. ( Liu, W; Lü, B; Xiao, S, 1996) |
| "Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg, 10 mg or identical placebo, for 4 weeks." | 5.08 | Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). ( Duckworth, M; Kordecki, H; Meineche-Schmidt, V; Pap, A; Paré, P; Räisänen, P; Schmid, V; Talley, NJ, 1998) |
| "We performed a randomized, placebo-controlled trial comparing the efficacy of treatment for two weeks with 20 mg of omeprazole orally twice daily, 500 mg of amoxicillin three times daily (with 500 mg of tetracycline three times daily substituted for amoxicillin in patients allergic to penicillin), and 400 mg of metronidazole three times daily (160 patients) with that of omeprazole alone (158 patients) for resolving symptoms of dyspepsia in patients with H." | 5.08 | Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. ( Dickson, A; El-Nujumi, A; El-Omar, E; Hilditch, T; Kelman, A; Knill-Jones, R; McColl, K; Murray, L; Penny, C; Wirz, A, 1998) |
| "Thirty-five consecutive patients (median age: 50 years, 17 men and 18 women) suffering from Helicobacter pylori associated peptic ulcer disease (duodenal ulcer: n = 15, gastric ulcer: n = 13) or severe functional dyspepsia (n = 7) were enrolled in a two-center clinical trial and treated with omeprazole 20 mg bid preprandially and roxithromycin 300 mg bid postprandially over two weeks." | 5.07 | [Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?]. ( Adamek, RJ; Börsch, G; Labenz, J; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| "In a randomized, placebo-controlled, double-blind, crossover comparison, 12 patients with congestive heart failure (New York Heart Association class II) and dyspeptic complaints were treated orally for 1 week each with placebo, 40 mg omeprazole daily, and 40 mg famotidine daily." | 5.07 | Cardiovascular effects of omeprazole and famotidine. ( Halabi, A; Kirch, W, 1992) |
| "In an open study, 62 patients with Helicobacter pylori-associated ulcer disease or functional dyspepsia were treated for two weeks with 2 x 20 mg omeprazole preprandially and 4 x 500 mg amoxicillin suspension one hour before meals and at night." | 5.07 | Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1992) |
| " Studies indicate that the omeprazole test is the most sensitive and cost effective test for diagnosing gastro-oesophageal reflux disease (GORD) in patients with extra-oesophageal or more "classic" symptoms suggestive of GORD." | 4.81 | Use of antisecretory agents as a trial of therapy. ( Fennerty, MB, 2002) |
| " In triple therapy, two studies used the same regimen in nonulcer dyspepsia patients: lansoprazole 30 mg/day for 2 weeks, amoxicillin 2 g/day for 2 weeks, and tinidazole 1 g/day for 2 weeks." | 4.78 | Effect of lansoprazole on Helicobacter pylori. ( Lamouliatte, H, 1993) |
| "The results of placebo-controlled clinical trials of the treatment of non-ulcer dyspepsia with antacids, H2-receptor blockers, pirenzepine, sucralfate and colloidal bismuth subcitrate are reviewed." | 4.78 | [Drug therapy of non-ulcer dyspepsia]. ( Bytzer, P, 1991) |
| " Those who tested positive for giardiasis (Group 1) were assigned to receive Tinidazole 2." | 3.79 | Giardia intestinalis in patients with nonulcer dyspepsia. ( Abulhasan, M; Albadry, A; Eida, M; Elshazly, TA, 2013) |
| "Patients who had heartburn twice a week or more were treated with 20 mg omeprazole (OPZ) once daily for 8 wk as an initial therapy (study 1)." | 3.77 | Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. ( Fujiwara, A; Ishioka, H; Kawahara, Y; Nasu, J; Okada, H; Takenaka, R; Tsuzuki, T; Yamamoto, K; Yoshinaga, F, 2011) |
| "Although no strategy was the indisputable cost effective option, CanDys omeprazole may be the strategy of choiceover a clinically relevant range of WTP assumptions in the initial management of Canadian patients with uninvestigated dyspepsia." | 3.76 | A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Crott, R; Escobedo, S; Fallone, CA; Kalra, H; Kennedy, WA; Lachaine, J; Levinton, C; Nevin, K; Sinclair, P; Smyth, S; Thomson, A; Veldhuyzen van Zanten, S; White, R, 2010) |
| " Adverse events that occurred significantly more often in the first month of treatment with esomeprazole compared with months 2-6 included diarrhoea, nausea/vomiting, abdominal pain, dyspepsia, headache/migraine, intolerance, malaise/lassitude, pruritus, unspecified adverse effects and abnormal sensation." | 3.74 | Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England. ( Davies, M; Shakir, SA; Wilton, LV, 2008) |
| "This pragmatic, primary care study by Meineche-Schmidt in patients with presumed acid-related uninvestigated dyspepsia showed that a standard dose of omeprazole 20 mg daily was significantly more effective than a placebo in treating their self-worded main dyspepsia complaint." | 3.72 | Treat the patients' main dyspepsia complaint, not the ROME criteria. ( Chiba, N, 2004) |
| " pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o." | 3.70 | Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998) |
| " A further evaluation was undertaken in patients with symptoms suggestive of GERD and in patients with non-ulcer dyspepsia, to identify factors that might predict symptom relief during treatment with omeprazole." | 3.70 | The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. ( Bolling-Sternevald, E; Carlsson, R; Dent, J; Johnsson, F; Junghard, O; Lauritsen, K; Lundell, L; Riley, S, 1998) |
| " Sixty-six patients (with nonulcer dyspepsia, inactive ulcer, or active ulcer) were given lansoprazole (30 mg, h." | 3.69 | Endoscopic topical therapy for the treatment of Helicobacter pylori infection. ( Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y, 1996) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "Dyspepsia is a common symptom with a broad differential diagnosis and complex pathophysiology which annually affect about 25% of the general population." | 2.82 | Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms. ( Hemati, K; Jodaki, A; Peyman, H; Sahraie, A; Yasemi, M; Yasemi, MR, 2016) |
| "In case of symptom recurrence, an endoscopy was performed." | 2.75 | Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. ( Bytzer, P; Reimer, C, 2010) |
| "A new questionnaire for assessing gastroesophageal reflux disease (GERD), the Frequency Scale for Symptoms of GERD, covers the 12 most common symptoms of GERD patients." | 2.73 | Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. ( Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H, 2007) |
| " Patients were randomized double-blindly to taper down or continue a constant dosage of omeprazole for three weeks." | 2.72 | Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. ( Abrahamsson, H; Agerforz, P; Björnsson, E; Jensen, C; Kilander, A; Mattsson, N; Simrén, M, 2006) |
| "Levodopa was prescribed for groups 1 and 3." | 2.72 | Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. ( Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR, 2006) |
| " Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0." | 2.71 | Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. ( Biagini, R; Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansi, C; Mele, MR; Savarino, V; Tessieri, L; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Peptic ulcer was found in 6." | 2.71 | Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. ( Färkkilä, M; Sarna, S; Sipponen, P; Valtonen, V, 2004) |
| "A urea breath test was performed 1-2 months after eradication." | 2.71 | Eradication rate of Helicobacter pylori in dyspeptic patients. ( Amini, M; Khedmat, H; Yari, F, 2005) |
| "Treatment with omeprazole provides superior symptom relief compared to ranitidine, cisapride, and placebo in the treatment of H." | 2.71 | A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Lee, J; Sinclair, P; Smyth, S; Thomson, A; Veldhuyzen van Zanten, SJ, 2005) |
| "Helicobacter pylori gastritis is usually a lifelong disease which can cause different topographical inflammatory reactions and induce divergent effects on acid secretion in humans." | 2.70 | Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia. ( Färkkilä, M; Koskenpato, J; Sipponen, P, 2002) |
| "A urea breath test was performed 1 month after the end of therapy; patients and investigators were blind to the results." | 2.70 | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. ( Dhir, V; Laine, L, 2002) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | 2.69 | One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "Omeprazole was better tolerated than misoprostol." | 2.69 | Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. ( Barkun, A; Hawkey, CJ; Karrasch, JA; Swannell, AJ; Szczepañski, L; Walker, DG; Yeomans, ND, 1998) |
| "Omeprazole is an effective agent for gastroduodenal prophylaxis in patients taking NSAIDs." | 2.69 | Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. ( Bardhan, KD; Cullen, D; Eisner, M; Hawkey, CJ; Kogut, DG; Peacock, RA; Thomson, JM, 1998) |
| "Pretreatment with omeprazole did not reduce the cure rate for this new quadruple therapy." | 2.69 | A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. ( Maeda, K; Nishimura, H; Oda, K; Ohkuma, K; Okabe, N; Okada, M; Oki, K; Seo, M; Shirotani, T, 1998) |
| "pylori functional dyspepsia is prevalent in people over 60 years old." | 2.69 | Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Chodash, HB; Dawson, BK; Luca, S; Michalos, A; Terranova, R, 1999) |
| "After eradication, 51 out of 53 treated rosacea patients became Hp negative." | 2.69 | Helicobacter pylori and its eradication in rosacea. ( Bielański, W; Karczewska, E; Konturek, SJ; Pytko-Polonczyk, J; Sliwowski, Z; Szlachcic, A, 1999) |
| "Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely." | 2.69 | Identifying responders to acid suppression in dyspepsia using a random starting day trial. ( Bonnevie, O; Breinstrup, H; Bytzer, P; Funch-Jensen, P; Hansen, JM; Matzen, P; Meineche-Schmidt, V; Rune, S; Schaffalitzky De Muckadell, OB, 2000) |
| "Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole." | 2.68 | Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. ( Andrews, P; Bae, H; Borody, TJ; Brandl, S; Fracchia, G; Shortis, NP, 1995) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| "We determined the effect of four times daily dosing with intravenous omeprazole on 24-h intragastric acidity, serum gastrin, and serum pepsinogen A and C in 10 fasting subjects (median age, 23." | 2.67 | Repeated intravenous bolus injections of omeprazole: effects on 24-hour intragastric pH, serum gastrin, and serum pepsinogen A and C. ( Baak, LC; Biemond, I; Jansen, JB; Lamers, CB, 1991) |
| "A diagnosis of toxic epidermal necrolysis (TEN) was made." | 2.45 | Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. ( Burke, A; Burns, A; Handfield-Jones, S; Palmer, M; Sinha, A; Thakor, AS, 2009) |
| "Lansoprazole is an inhibitor of gastric acid secretion and also exhibits antibacterial activity against Helicobacter pylori in vitro." | 2.41 | Lansoprazole: an update of its place in the management of acid-related disorders. ( Jarvis, B; Matheson, AJ, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Dyspepsia is a common condition in the general population but data are lacking on the benefits of effective acid inhibition with proton pump inhibitors in functional dyspepsia." | 2.41 | The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. ( Lauritsen, K; Talley, NJ, 2002) |
| "Alopecia areata is a disease of the hair follicles, with strong evidence supporting autoimmune etiology." | 1.37 | Cure of alopecia areata after eradication of Helicobacter pylori: a new association? ( Campuzano-Maya, G, 2011) |
| " However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy." | 1.36 | Editorial: just how "difficult" is it to withdraw PPI treatment? ( Howden, CW; Kahrilas, PJ, 2010) |
| "Gastro-oesophageal reflux disease is one of the most common diseases in primary care and has a significant negative impact on patients' quality of life." | 1.33 | Validation of the Reflux Disease Questionnaire for a German population. ( Kulig, M; Leodolter, A; Malfertheiner, P; Nocon, M; Willich, SN, 2005) |
| "Acute interstitial nephritis is an uncommon but important cause of acute renal failure." | 1.33 | Rabeprazole-induced acute interstitial nephritis. ( Coleman, PL; Geevasinga, N; Roger, SD, 2005) |
| "pylori in children with type 1 diabetes mellitus improves their metabolic control." | 1.32 | Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. ( Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A, 2004) |
| "Metronidazole resistance was significantly more common in women (P < 0." | 1.32 | Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001. ( Baldwin, L; Bell, GD; Cameron, EAB; Jones, P; Powell, KU; Williams, SGJ, 2004) |
| "Presence of a gastroduodenal ulcer, age, gender and smoking habit did not differ significantly between the eradicated and noneradicated groups." | 1.31 | Failure of Helicobacter pylori eradication: is poor compliance the main cause? ( Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G, 2002) |
| "To evaluate management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in the setting of family practice." | 1.31 | [Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care]. ( Azagra, R; Calvet, X; Cubells, MJ; Gené, E; López, T, 2002) |
| "When omeprazole was re-started she developed fever and acute renal failure, which again settled quickly on discontinuation of omeprazole." | 1.30 | Pyrexia, anaemia and acute renal failure secondary to omeprazole. ( Arnold, IR; Ferner, RE; Landray, MJ; Ringrose, T, 1998) |
| "[14C]Urea breath tests were performed in 20 H." | 1.30 | Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. ( El-Nujumi, A; Hilditch, TE; McColl, KE; Williams, C, 1998) |
| "In patients with systemic sclerosis peristaltic abnormalities may delay gastric emptying, giving rise to bacterial overgrowth, including possibly Helicobacter pylori (HP)." | 1.29 | Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication. ( Goerz, G; Humfeld, S; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 104 (34.44) | 18.2507 |
| 2000's | 169 (55.96) | 29.6817 |
| 2010's | 25 (8.28) | 24.3611 |
| 2020's | 4 (1.32) | 2.80 |
| Authors | Studies |
|---|---|
| Yongwatana, K | 1 |
| Harinwan, K | 1 |
| Chirapongsathorn, S | 1 |
| Opuchar, K | 1 |
| Sanpajit, T | 1 |
| Piyanirun, W | 1 |
| Puttapitakpong, C | 1 |
| Corazziari, ES | 1 |
| Gasbarrini, A | 5 |
| D'Alba, L | 1 |
| D'Ovidio, V | 1 |
| Riggio, O | 1 |
| Passaretti, S | 1 |
| Annibale, B | 1 |
| Cicala, M | 1 |
| Repici, A | 1 |
| Bassotti, G | 1 |
| Ciacci, C | 1 |
| Di Sabatino, A | 1 |
| Neri, M | 2 |
| Bragazzi, MC | 1 |
| Ribichini, E | 1 |
| Radocchia, G | 1 |
| Iovino, P | 1 |
| Marazzato, M | 1 |
| Schippa, S | 1 |
| Badiali, D | 1 |
| Kongkam, P | 1 |
| Khongkha, W | 1 |
| Lopimpisuth, C | 1 |
| Chumsri, C | 1 |
| Kosarussawadee, P | 1 |
| Phutrakool, P | 1 |
| Khamsai, S | 1 |
| Sawanyawisuth, K | 1 |
| Sura, T | 1 |
| Phisalprapa, P | 1 |
| Buamahakul, T | 1 |
| Siwamogsatham, S | 1 |
| Angsusing, J | 1 |
| Poonniam, P | 1 |
| Wanaratna, K | 1 |
| Teerachaisakul, M | 1 |
| Pongpirul, K | 1 |
| Valencia, ME | 1 |
| Montejano, R | 1 |
| Moreno, V | 2 |
| Martín Carbonero, L | 1 |
| Bernardino, JI | 1 |
| Serrano, L | 1 |
| Sharifi, R | 1 |
| Nouri, M | 1 |
| Eidi, A | 1 |
| Noormohammadi, Z | 1 |
| Dolatkhah, H | 1 |
| Shirmohammadi, M | 1 |
| Zullo, A | 5 |
| Scaccianoce, G | 1 |
| De Francesco, V | 6 |
| Ruggiero, V | 1 |
| D'Ambrosio, P | 1 |
| Castorani, L | 1 |
| Bonfrate, L | 1 |
| Vannella, L | 1 |
| Hassan, C | 3 |
| Portincasa, P | 1 |
| Abulhasan, M | 1 |
| Elshazly, TA | 1 |
| Eida, M | 1 |
| Albadry, A | 1 |
| Sezgin, O | 1 |
| Barlas, IO | 1 |
| Uçbilek, E | 1 |
| Yengel, E | 1 |
| Altintaş, E | 1 |
| Hosseini, SM | 1 |
| Sharifipoor, F | 1 |
| Nazemian, F | 1 |
| Ghanei, H | 1 |
| Zivarifar, HR | 1 |
| Fakharian, T | 1 |
| Tsuchie, SY | 1 |
| Nani, FS | 1 |
| Vieira, JE | 1 |
| Yan, XJ | 1 |
| Li, WT | 1 |
| Chen, X | 1 |
| Wang, EM | 1 |
| Liu, Q | 1 |
| Qiu, HY | 1 |
| Cao, ZJ | 1 |
| Chen, SL | 1 |
| Vardi, M | 1 |
| Cryer, BL | 2 |
| Cohen, M | 2 |
| Lanas, A | 3 |
| Schnitzer, TJ | 2 |
| Lapuerta, P | 2 |
| Goldsmith, MA | 2 |
| Laine, L | 4 |
| Doros, G | 2 |
| Liu, Y | 2 |
| McIntosh, AI | 1 |
| Cannon, CP | 2 |
| Bhatt, DL | 2 |
| Vaduganathan, M | 1 |
| Hsieh, WH | 1 |
| Shook, TL | 1 |
| Jodaki, A | 1 |
| Sahraie, A | 1 |
| Yasemi, M | 1 |
| Peyman, H | 1 |
| Yasemi, MR | 1 |
| Hemati, K | 1 |
| Paroni Sterbini, F | 1 |
| Palladini, A | 1 |
| Masucci, L | 1 |
| Cannistraci, CV | 1 |
| Pastorino, R | 1 |
| Ianiro, G | 1 |
| Bugli, F | 1 |
| Martini, C | 1 |
| Ricciardi, W | 1 |
| Sanguinetti, M | 1 |
| Cammarota, G | 4 |
| Posteraro, B | 1 |
| Nabinger, DD | 1 |
| Mazzoleni, LE | 4 |
| Sander, GB | 4 |
| Mazzoleni, F | 2 |
| Osório, MC | 1 |
| Klein, MG | 1 |
| Rech, TF | 1 |
| Basso da Silva, L | 1 |
| de Moraes, GS | 1 |
| Cristovam, RA | 1 |
| Nardelli, EF | 1 |
| Francesconi, CF | 4 |
| Simon, D | 1 |
| Geva, A | 1 |
| Sabo, E | 1 |
| Levy, J | 1 |
| Blumenthal, M | 1 |
| Ophir, E | 1 |
| Geva, H | 1 |
| Bornstein, J | 1 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Pellicano, R | 1 |
| Gwee, KA | 1 |
| Teng, L | 1 |
| Wong, RK | 1 |
| Ho, KY | 1 |
| Sutedja, DS | 1 |
| Yeoh, KG | 1 |
| McColl, KE | 5 |
| Gillen, D | 1 |
| Zhou, GY | 1 |
| Zhou, GS | 1 |
| Jian-hong, J | 1 |
| Thakor, AS | 1 |
| Burke, A | 1 |
| Handfield-Jones, S | 1 |
| Sinha, A | 1 |
| Palmer, M | 1 |
| Burns, A | 1 |
| Molloy, D | 1 |
| Molloy, A | 1 |
| O'Loughlin, C | 1 |
| Falconer, M | 1 |
| Hennessy, M | 1 |
| Burkov, SG | 1 |
| Arutiunov, AT | 1 |
| Okoemov, MN | 1 |
| Anokhina, LN | 1 |
| Egorova, NV | 1 |
| Makukh, EA | 1 |
| Chugunnikova, LI | 1 |
| Jakobsson, HE | 1 |
| Jernberg, C | 1 |
| Andersson, AF | 1 |
| Sjölund-Karlsson, M | 1 |
| Jansson, JK | 1 |
| Engstrand, L | 1 |
| Howden, CW | 1 |
| Kahrilas, PJ | 1 |
| Reimer, C | 2 |
| Bytzer, P | 8 |
| Barkun, AN | 3 |
| Crott, R | 1 |
| Fallone, CA | 1 |
| Kennedy, WA | 1 |
| Lachaine, J | 1 |
| Levinton, C | 1 |
| Armstrong, D | 7 |
| Chiba, N | 7 |
| Thomson, A | 2 |
| Veldhuyzen van Zanten, S | 2 |
| Sinclair, P | 5 |
| Escobedo, S | 5 |
| Chakraborty, B | 3 |
| Smyth, S | 3 |
| White, R | 1 |
| Kalra, H | 1 |
| Nevin, K | 2 |
| Alqutub, AN | 1 |
| Masoodi, I | 1 |
| Yakoob, J | 1 |
| Abid, S | 1 |
| Abbas, Z | 1 |
| Jafri, SN | 1 |
| Bjornsson, E | 2 |
| Tsuzuki, T | 1 |
| Okada, H | 1 |
| Kawahara, Y | 1 |
| Takenaka, R | 1 |
| Nasu, J | 1 |
| Ishioka, H | 1 |
| Fujiwara, A | 1 |
| Yoshinaga, F | 1 |
| Yamamoto, K | 1 |
| Campuzano-Maya, G | 1 |
| Uchoa, DM | 3 |
| De Bona, LR | 1 |
| Milbradt, TC | 1 |
| Von Reisswitz, PS | 1 |
| Berwanger, O | 1 |
| Bressel, M | 1 |
| Edelweiss, MI | 3 |
| Marini, SS | 1 |
| Molina, CG | 1 |
| Folador, L | 1 |
| Lunkes, RP | 1 |
| Heck, R | 1 |
| Birkhan, OA | 1 |
| Spindler, BM | 1 |
| Katz, N | 1 |
| Colombo, Bda S | 1 |
| Guerrieri, PP | 1 |
| Renck, LB | 1 |
| Grando, E | 1 |
| Hocevar de Moura, B | 1 |
| Dahmer, FD | 1 |
| Rauber, J | 1 |
| Prolla, JC | 3 |
| Sakurai, K | 1 |
| Nagahara, A | 5 |
| Inoue, K | 1 |
| Akiyama, J | 1 |
| Mabe, K | 1 |
| Suzuki, J | 1 |
| Habu, Y | 1 |
| Araki, A | 1 |
| Suzuki, T | 1 |
| Satoh, K | 2 |
| Nagami, H | 1 |
| Harada, R | 1 |
| Tano, N | 1 |
| Kusaka, M | 1 |
| Fujioka, Y | 1 |
| Fujimura, T | 1 |
| Shigeto, N | 1 |
| Oumi, T | 1 |
| Miwa, J | 1 |
| Miwa, H | 6 |
| Fujimoto, K | 1 |
| Kinoshita, Y | 1 |
| Haruma, K | 3 |
| Labenz, J | 7 |
| Blum, AL | 7 |
| Bolten, WW | 1 |
| Dragosics, B | 1 |
| Rösch, W | 1 |
| Stolte, M | 8 |
| Koelz, HR | 3 |
| Kazim, F | 1 |
| Gervais, M | 1 |
| Pyzyk, M | 1 |
| Boixeda, D | 1 |
| Bermejo, F | 1 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 1 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Koskenpato, J | 2 |
| Färkkilä, M | 3 |
| Sipponen, P | 3 |
| Nyrén, O | 1 |
| Wong, WM | 5 |
| Wong, BC | 5 |
| Hung, WK | 1 |
| Yee, YK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Fung, FM | 2 |
| Tong, TS | 2 |
| Lai, KC | 5 |
| Hu, WH | 3 |
| Yuen, MF | 1 |
| Lam, SK | 5 |
| Rosandić, M | 1 |
| Pilas, V | 1 |
| Bevanda, M | 2 |
| Falisevac, V | 1 |
| Korać, B | 1 |
| Faleo, D | 2 |
| Panella, C | 4 |
| Ierardi, E | 6 |
| Margiotta, M | 2 |
| Bago, J | 1 |
| Halle, ZB | 1 |
| Strinić, D | 1 |
| Kućisec, N | 1 |
| Jandrić, D | 1 |
| Tomić, M | 1 |
| Bilić, A | 1 |
| Tsukada, K | 1 |
| Miyazaki, T | 1 |
| Katoh, H | 1 |
| Masuda, N | 1 |
| Ojima, H | 1 |
| Fukai, Y | 1 |
| Nakajima, M | 1 |
| Manda, R | 1 |
| Fukuchi, M | 1 |
| Kuwano, H | 1 |
| Tsukada, O | 1 |
| Arnold, R | 2 |
| Fischer, M | 2 |
| Rabeneck, L | 3 |
| Souchek, J | 3 |
| Wristers, K | 3 |
| Menke, T | 2 |
| Ambriz, E | 2 |
| Huang, I | 1 |
| Wray, N | 1 |
| Murakami, K | 1 |
| Sato, R | 1 |
| Okimoto, T | 1 |
| Nasu, M | 1 |
| Fujioka, T | 1 |
| Kodama, M | 1 |
| Kagawa, J | 1 |
| Patel, AS | 1 |
| Pohl, JF | 1 |
| Easley, DJ | 1 |
| Bolling-Sternevald, E | 8 |
| Lauritsen, K | 6 |
| Aalykke, C | 1 |
| Havelund, T | 3 |
| Knudsen, T | 1 |
| Unge, P | 2 |
| Ekström, P | 2 |
| Jaup, B | 1 |
| Norrby, A | 1 |
| Stubberöd, A | 2 |
| Melén, K | 1 |
| Carlsson, R | 2 |
| Jerndal, P | 2 |
| Junghard, O | 6 |
| Glise, H | 3 |
| Vaira, D | 1 |
| Vakil, N | 3 |
| Gatta, L | 1 |
| Ricci, C | 1 |
| Menegatti, M | 1 |
| Tampieri, A | 1 |
| Perna, F | 1 |
| Rinaldi, V | 2 |
| Perri, F | 1 |
| Papadìa, C | 1 |
| Fornari, F | 1 |
| Pilati, S | 1 |
| Mete, LS | 1 |
| Merla, A | 1 |
| Potì, R | 1 |
| Marinone, G | 1 |
| Savioli, A | 1 |
| Campo, SM | 1 |
| Miglioli, M | 1 |
| Morini, S | 3 |
| Dulbecco, P | 2 |
| Gambaro, C | 2 |
| Bilardi, C | 2 |
| Zentilin, P | 2 |
| Mele, MR | 1 |
| Mansi, C | 1 |
| Biagini, R | 1 |
| Tessieri, L | 1 |
| Iiritano, E | 2 |
| Usai, P | 2 |
| Vigneri, S | 2 |
| Savarino, V | 2 |
| Xia, HH | 3 |
| Talley, NJ | 14 |
| O'Morain, CA | 2 |
| Mitchell, HM | 1 |
| Manes, G | 1 |
| Menchise, A | 1 |
| de Nucci, C | 1 |
| Balzano, A | 1 |
| Kamada, T | 2 |
| Hata, J | 1 |
| Kusunoki, H | 1 |
| Sasaki, A | 1 |
| Ito, M | 2 |
| Tanaka, S | 1 |
| Yoshihara, M | 2 |
| Santarelli, L | 1 |
| Gabrielli, M | 1 |
| Candelli, M | 2 |
| Cremonini, F | 1 |
| Nista, EC | 3 |
| Gasbarrini, G | 4 |
| Dore, MP | 1 |
| Marras, L | 1 |
| Maragkoudakis, E | 1 |
| Nieddu, S | 1 |
| Manca, A | 1 |
| Graham, DY | 1 |
| Realdi, G | 1 |
| Malfertheiner, P | 7 |
| MOssner, J | 1 |
| Fischbach, W | 1 |
| Layer, P | 1 |
| Leodolter, A | 4 |
| Demleitner, K | 1 |
| Fuchs, W | 1 |
| Fedorak, RN | 1 |
| Lambert, J | 1 |
| Cohen, L | 1 |
| Vanjaka, A | 1 |
| Lara, LF | 1 |
| Cisneros, G | 1 |
| Gurney, M | 1 |
| Van Ness, M | 1 |
| Jarjoura, D | 1 |
| Moauro, B | 1 |
| Polen, A | 1 |
| Rutecki, G | 1 |
| Whittier, F | 1 |
| Milano, A | 1 |
| Laterza, F | 1 |
| Di Bonaventura, G | 1 |
| Piccolomini, R | 1 |
| Caldarella, MP | 1 |
| Balatsinou, C | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Chu, KM | 2 |
| Hui, WM | 2 |
| Kwok, KF | 1 |
| Hu, HC | 1 |
| Chan, OO | 1 |
| Chan, CK | 3 |
| Takahashi, S | 2 |
| Füessl, HS | 1 |
| Mansia, C | 1 |
| Ojetti, V | 1 |
| Migneco, A | 1 |
| Zocco, MA | 1 |
| González Carro, P | 1 |
| Legaz Huidobro, ML | 1 |
| Pérez Roldán, F | 1 |
| Esteban López Jamar, JM | 1 |
| Valenzuela Gámez, JC | 1 |
| Ponte Tellechea, A | 1 |
| Ruiz Carrillo, F | 1 |
| Pedraza Martín, C | 1 |
| Díaz de Rojas, F | 1 |
| Sáez Bravo, JM | 1 |
| Marangi, S | 1 |
| Burattini, O | 1 |
| Berloco, P | 1 |
| Russo, F | 1 |
| Barone, M | 1 |
| Di Leo, A | 2 |
| Minenna, MF | 2 |
| Stoppino, V | 3 |
| Francavilla, A | 2 |
| Veldhuyzen Van Zanten, SJ | 7 |
| Grace, E | 2 |
| Lee, J | 2 |
| Barkun, A | 3 |
| Thomson, AB | 3 |
| Romano, M | 1 |
| Marmo, R | 1 |
| Cuomo, A | 1 |
| De Simone, T | 1 |
| Mucherino, C | 1 |
| Iovene, MR | 1 |
| Montella, F | 1 |
| Tufano, MA | 1 |
| Del Vecchio Blanco, C | 1 |
| Nardone, G | 1 |
| Peitz, U | 2 |
| Raps, S | 1 |
| Plein, K | 1 |
| Hotz Dagger, J | 1 |
| Rigante, D | 1 |
| Marietti, G | 1 |
| Crea, F | 1 |
| Schiavino, A | 1 |
| Pignataro, G | 1 |
| Petrucci, S | 1 |
| Della Valle, N | 2 |
| Amoruso, A | 1 |
| Muscatiello, N | 1 |
| Sarna, S | 1 |
| Valtonen, V | 1 |
| Laheij, RJ | 3 |
| Hermsen, JT | 1 |
| Jansen, JB | 4 |
| Horrevorts, AM | 1 |
| Rongen, RJ | 1 |
| Van Rossum, LG | 1 |
| Witteman, E | 1 |
| de Koning, RW | 1 |
| Peura, DA | 2 |
| Kovacs, TO | 1 |
| Metz, DC | 1 |
| Siepman, N | 1 |
| Pilmer, BL | 1 |
| Cameron, EAB | 1 |
| Powell, KU | 2 |
| Baldwin, L | 1 |
| Jones, P | 1 |
| Bell, GD | 2 |
| Williams, SGJ | 1 |
| Di Mario, F | 2 |
| Ingegnoli, A | 1 |
| Dal Bò, N | 2 |
| Cavestro, GM | 1 |
| Moussa, AM | 1 |
| Cavallaro, LG | 1 |
| Aragona, G | 1 |
| Iori, V | 1 |
| Pilotto, A | 1 |
| Franzè, A | 1 |
| Rugge, M | 2 |
| Meineche-Schmidt, V | 7 |
| Saribas, S | 1 |
| Kocazeybek, B | 1 |
| Aslan, M | 1 |
| Altun, S | 1 |
| Seyhun, Y | 1 |
| Öner, YA | 1 |
| Memisoglu, N | 1 |
| Pietrini, L | 1 |
| Winn, S | 1 |
| Monno, R | 1 |
| Madsen, LG | 3 |
| Wallin, L | 1 |
| Lee, KJ | 1 |
| Demarchi, B | 1 |
| Demedts, I | 1 |
| Sifrim, D | 1 |
| Raeymaekers, P | 1 |
| Tack, J | 1 |
| Chan, FK | 1 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Wu, JC | 1 |
| Leung, WK | 1 |
| Lee, YT | 1 |
| To, KF | 1 |
| Chung, SC | 1 |
| Sung, JJ | 1 |
| Buzás, GM | 1 |
| Agar, M | 1 |
| Webster, R | 1 |
| Lacey, J | 1 |
| Donovan, B | 1 |
| Walker, A | 1 |
| Xiao, SD | 2 |
| Hu, PJ | 1 |
| Wang, WH | 1 |
| Gu, Q | 1 |
| Huang, JQ | 1 |
| Wu, SM | 2 |
| Li, CJ | 1 |
| Chen, MH | 1 |
| Cui, Y | 1 |
| Nocon, M | 1 |
| Kulig, M | 1 |
| Willich, SN | 1 |
| Garza-González, E | 1 |
| Tijerina-Menchaca, R | 1 |
| Pérez-Pérez, GI | 1 |
| Bosques-Padilla, FJ | 1 |
| Geevasinga, N | 2 |
| Coleman, PL | 2 |
| Roger, SD | 2 |
| Gerson, LB | 1 |
| Triadafilopoulos, G | 1 |
| Magistà, AM | 1 |
| Castellaneta, S | 1 |
| Miniello, VL | 1 |
| Lionetti, E | 1 |
| Ros, P | 1 |
| Rigillo, N | 1 |
| Francavilla, R | 1 |
| Amini, M | 1 |
| Khedmat, H | 1 |
| Yari, F | 1 |
| Ruiz García, A | 1 |
| Gordillo López, FJ | 1 |
| Hermosa Hernán, JC | 1 |
| Arranz Martínez, E | 1 |
| Villares Rodríguez, JE | 1 |
| Stasi, R | 1 |
| Rossi, Z | 1 |
| Stipa, E | 1 |
| Amadori, S | 1 |
| Newland, AC | 1 |
| Provan, D | 1 |
| White, RJ | 1 |
| Ott, EA | 2 |
| Wortmann, AC | 2 |
| Theil, AL | 2 |
| Somm, G | 1 |
| Cartell, A | 2 |
| Rivero, LF | 2 |
| Huang, J | 1 |
| Cheung, KL | 1 |
| Ho, VY | 1 |
| Chan, AO | 2 |
| Hui, CK | 1 |
| García-Altés, A | 1 |
| Rota, R | 1 |
| Barenys, M | 1 |
| Abad, A | 1 |
| Pons, JM | 1 |
| Piqué, JM | 1 |
| Calvet, X | 2 |
| Ducons, J | 1 |
| Bujanda, L | 1 |
| Bory, F | 1 |
| Montserrat, A | 1 |
| Gisbert, JP | 1 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Natan-Eisig, J | 1 |
| Paraíso-Ferraz, JG | 1 |
| Trevisan, M | 1 |
| Zaterkaad, S | 1 |
| Suzuki, H | 1 |
| Masaoka, T | 1 |
| Sakai, G | 1 |
| Ishii, H | 1 |
| Hibi, T | 1 |
| Uygun, A | 1 |
| Kadayifçi, A | 1 |
| Yeşilova, Z | 1 |
| Savaş, MC | 1 |
| Ateş, Y | 1 |
| Karslioğlu, Y | 1 |
| Ciğerim, M | 1 |
| Bağci, S | 1 |
| Dağalp, K | 1 |
| Güliter, S | 1 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Wong, J | 1 |
| Barros, SG | 1 |
| Polanczyk, CA | 1 |
| Fritscher, LG | 1 |
| Mann, V | 1 |
| Lule, GN | 1 |
| Webster, AC | 1 |
| Tan, HJ | 1 |
| Rizal, AM | 1 |
| Rosmadi, MY | 1 |
| Goh, KL | 2 |
| Jarbol, DE | 2 |
| Kragstrup, J | 2 |
| Stovring, H | 1 |
| Schaffalitzky de Muckadell, OB | 4 |
| Ji, KY | 1 |
| Hu, FL | 1 |
| Abrahamsson, H | 1 |
| Simrén, M | 1 |
| Mattsson, N | 1 |
| Jensen, C | 1 |
| Agerforz, P | 1 |
| Kilander, A | 1 |
| Bech, M | 2 |
| Emami, MH | 1 |
| Saberfiroozi, MM | 1 |
| Arj, A | 1 |
| Taghavi, AR | 1 |
| Bagheri-Lankarani, K | 1 |
| Dehbashi, N | 1 |
| Fattahi, MR | 1 |
| Alizadeh, M | 1 |
| Kaviani, MJ | 1 |
| Bahri-Najafi, R | 1 |
| Geramizadeh, B | 1 |
| Esmaeili, A | 1 |
| Duggan, AE | 1 |
| Kusano, M | 1 |
| Shimoyama, Y | 1 |
| Kawamura, O | 1 |
| Maeda, M | 1 |
| Kuribayashi, S | 1 |
| Nagoshi, A | 1 |
| Zai, H | 1 |
| Moki, F | 1 |
| Horikoshi, T | 1 |
| Toki, M | 1 |
| Sugimoto, S | 1 |
| Mori, M | 1 |
| Kjeldsen, HC | 1 |
| Christensen, B | 1 |
| Chung, SJ | 1 |
| Lee, DH | 1 |
| Kim, N | 1 |
| Jung, SH | 1 |
| Kim, JW | 1 |
| Hwang, JH | 1 |
| Park, YS | 1 |
| Lee, KH | 1 |
| Jung, HC | 2 |
| Song, IS | 1 |
| Stewart, D | 1 |
| John, D | 1 |
| Cunningham, S | 1 |
| McCaig, D | 1 |
| Hansford, D | 1 |
| Ford, AC | 1 |
| Forman, D | 2 |
| Nathan, J | 2 |
| Crocombe, WD | 1 |
| Axon, AT | 3 |
| Moayyedi, P | 3 |
| Oshima, T | 1 |
| Tomita, T | 1 |
| Desai, JC | 1 |
| Sanyal, SM | 1 |
| Goo, T | 1 |
| Benson, AA | 1 |
| Bodian, CA | 1 |
| Miller, KM | 1 |
| Cohen, LB | 1 |
| Aisenberg, J | 1 |
| Davies, M | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Hansen, JM | 2 |
| Wildner-Christensen, M | 1 |
| Hallas, J | 1 |
| Borody, TJ | 2 |
| Andrews, P | 1 |
| Fracchia, G | 1 |
| Brandl, S | 1 |
| Shortis, NP | 2 |
| Bae, H | 1 |
| Schepp, W | 1 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Contreras, L | 1 |
| Giglio, M | 1 |
| Ossa, P | 1 |
| Weitz, JC | 1 |
| Roberts, SJ | 1 |
| Bateman, DN | 1 |
| Kreiss, C | 1 |
| Tillenburg, B | 2 |
| Becker, T | 2 |
| Börsch, G | 5 |
| Reinauer, S | 1 |
| Goerz, G | 1 |
| Ruzicka, T | 1 |
| Susanto, F | 1 |
| Humfeld, S | 1 |
| Reinauer, H | 1 |
| Trespi, E | 1 |
| Broglia, F | 1 |
| Villani, L | 1 |
| Luinetti, O | 1 |
| Fiocca, R | 2 |
| Solcia, E | 1 |
| Rühl, GH | 3 |
| Sollböhmer, M | 1 |
| Leverkus, F | 1 |
| Saha, N | 1 |
| Sachdev, A | 1 |
| Bhasin, DK | 1 |
| Sankaranahyanan, A | 1 |
| Khosla, PP | 1 |
| Singh, K | 1 |
| Sharma, PL | 1 |
| Wegener, M | 1 |
| Adamek, RJ | 3 |
| Opferkuch, W | 1 |
| Marchi, M | 1 |
| Vacondio, R | 1 |
| Bagnulo, A | 1 |
| Mengoli, M | 1 |
| Lamouliatte, H | 3 |
| Deltenre, M | 1 |
| Jonas, C | 1 |
| van Gossum, M | 1 |
| Buset, M | 1 |
| Otero, J | 1 |
| De Koster, E | 1 |
| Bertoni, G | 1 |
| Sassatelli, R | 1 |
| Nigrisoli, E | 1 |
| Tansini, P | 1 |
| Bianchi, G | 1 |
| Della Casa, G | 1 |
| Bagni, A | 1 |
| Bedogni, G | 1 |
| Grassi, SA | 1 |
| Cassaro, M | 1 |
| Donisi, PM | 1 |
| Vianello, F | 1 |
| Kusstatscher, S | 1 |
| Salandin, S | 1 |
| Grasso, GA | 1 |
| Ferrana, M | 1 |
| Battaglia, G | 1 |
| Davis, S | 1 |
| Weldon, MJ | 1 |
| Broadbent, A | 1 |
| Chambers, S | 1 |
| Mistry, R | 1 |
| Ranganath, L | 1 |
| Gould, SR | 1 |
| Tursi, A | 1 |
| Montalto, M | 1 |
| Papa, A | 1 |
| Veneto, G | 1 |
| Cuoco, L | 1 |
| Trua, F | 1 |
| Branca, G | 1 |
| Fedeli, G | 1 |
| Heikkinen, M | 1 |
| Pikkarainen, P | 1 |
| Takala, J | 1 |
| Julkunen, R | 1 |
| De Boer, WA | 5 |
| Driessen, WM | 3 |
| Tytgat, GN | 3 |
| Lai, JY | 2 |
| Geuskens, LM | 1 |
| Carling, L | 1 |
| Wetterhus, S | 2 |
| Wingren, PE | 1 |
| Anker-Hansen, O | 1 |
| Lundegårdh, G | 1 |
| Thorhallsson, E | 1 |
| Hackelsberger, A | 1 |
| Thor, P | 1 |
| Lorens, K | 1 |
| Tabor, S | 1 |
| Herman, R | 1 |
| Konturek, JW | 1 |
| Konturek, SJ | 2 |
| Lamers, CB | 4 |
| Kihira, K | 1 |
| Saifuku, K | 1 |
| Taniguchi, Y | 1 |
| Takimoto, T | 1 |
| Yoshida, Y | 1 |
| Ishino, Y | 1 |
| Yamamoto, H | 1 |
| Kimura, K | 1 |
| Bock, H | 1 |
| Mares, A | 1 |
| van Etten, RJ | 3 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 3 |
| van Unnik, AJ | 1 |
| Ebell, MH | 1 |
| Warbasse, L | 1 |
| Brenner, C | 1 |
| Jones, RH | 3 |
| Baxter, G | 1 |
| Chey, WD | 2 |
| Fisher, L | 1 |
| Elta, GH | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| DelValle, J | 1 |
| Hasler, WL | 1 |
| Scheiman, JM | 1 |
| Pugliano, F | 1 |
| Diana, F | 1 |
| Attili, AF | 1 |
| Buckley, MJ | 1 |
| Xia, HX | 1 |
| Hyde, DM | 1 |
| Keane, CT | 1 |
| Dobrucali, A | 1 |
| Tuncer, M | 1 |
| Eralp, YT | 1 |
| Goksel, S | 1 |
| Altin, M | 1 |
| Dinc, I | 1 |
| Szymanski, C | 2 |
| Pfaffenbach, B | 2 |
| van de Wouw, BA | 1 |
| Bobrzyński, A | 1 |
| Gedliczka, O | 1 |
| Bielański, W | 2 |
| Stachura, J | 1 |
| Konturek, S | 1 |
| Budzyński, A | 1 |
| Severens, JL | 2 |
| van de Lisdonk, EH | 2 |
| Verbeek, AL | 2 |
| Johnsson, F | 2 |
| Weywadt, L | 1 |
| Solhaug, JH | 1 |
| Hernqvist, H | 1 |
| Bengtsson, L | 1 |
| Hawkey, CJ | 3 |
| Karrasch, JA | 1 |
| Szczepañski, L | 2 |
| Walker, DG | 1 |
| Swannell, AJ | 1 |
| Yeomans, ND | 1 |
| Paramsothy, M | 1 |
| Azian, M | 1 |
| Parasakthi, N | 1 |
| Peh, SC | 1 |
| Bux, S | 1 |
| Lo, YL | 1 |
| Ong, KK | 1 |
| Lindsetmo, RO | 1 |
| Johnsen, R | 1 |
| Revhaug, A | 1 |
| Mason, I | 1 |
| Millar, LJ | 1 |
| Sheikh, RR | 1 |
| Evans, WM | 1 |
| Todd, PL | 1 |
| Turbitt, ML | 1 |
| Taylor, MD | 2 |
| Liu, W | 1 |
| Lü, B | 1 |
| Xiao, S | 1 |
| Tucci, A | 1 |
| Poli, L | 1 |
| Paparo, GF | 1 |
| Bocus, P | 1 |
| Togliani, T | 1 |
| Mazzoni, C | 1 |
| Orcioni, GF | 1 |
| Agosti, R | 1 |
| Grigioni, WF | 1 |
| Sottili, S | 1 |
| Caletti, G | 1 |
| Wiklund, I | 2 |
| Carlsson, J | 1 |
| Parente, F | 1 |
| Imbesi, V | 1 |
| Maconi, G | 1 |
| Cucino, C | 1 |
| Manzionna, G | 1 |
| Vago, L | 1 |
| Bianchi Porro, G | 1 |
| el-Nujumi, A | 3 |
| Murray, LS | 1 |
| el-Omar, EM | 1 |
| Dickson, A | 2 |
| Kelman, AW | 1 |
| Hilditch, TE | 2 |
| de Boer, SY | 1 |
| Siem, TH | 1 |
| Bigard, MA | 1 |
| Delchier, JC | 2 |
| Riachi, G | 1 |
| Thibault, P | 1 |
| Barthelemy, P | 2 |
| Cullen, D | 1 |
| Bardhan, KD | 1 |
| Eisner, M | 1 |
| Kogut, DG | 1 |
| Peacock, RA | 2 |
| Thomson, JM | 1 |
| Goves, J | 1 |
| Oldring, JK | 1 |
| Kerr, D | 1 |
| Dallara, RG | 1 |
| Roffe, EJ | 1 |
| Powell, JA | 1 |
| Améndola, R | 1 |
| Roldán, CD | 1 |
| Morgade, L | 1 |
| Solagna, A | 1 |
| Lineado, A | 1 |
| Musi, AO | 1 |
| Valero, J | 1 |
| Zerbo, O | 1 |
| Kogan, Z | 1 |
| Ferro, FE | 1 |
| Schenone, L | 1 |
| Corti, R | 1 |
| Tulassay, Z | 1 |
| van Rensburg, CJ | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Wason, CM | 1 |
| Gillon, KR | 1 |
| Okada, M | 1 |
| Oki, K | 1 |
| Shirotani, T | 1 |
| Seo, M | 1 |
| Okabe, N | 1 |
| Maeda, K | 1 |
| Nishimura, H | 1 |
| Ohkuma, K | 1 |
| Oda, K | 1 |
| Landray, MJ | 1 |
| Ringrose, T | 1 |
| Ferner, RE | 1 |
| Arnold, IR | 1 |
| Dent, J | 1 |
| Riley, S | 1 |
| Lundell, L | 1 |
| Williams, C | 1 |
| Reyes, E | 1 |
| Paré, P | 1 |
| Duckworth, M | 1 |
| Räisänen, P | 1 |
| Pap, A | 2 |
| Kordecki, H | 2 |
| Schmid, V | 2 |
| McColl, K | 1 |
| Murray, L | 1 |
| El-Omar, E | 1 |
| Wirz, A | 1 |
| Kelman, A | 1 |
| Penny, C | 1 |
| Knill-Jones, R | 1 |
| Hilditch, T | 1 |
| O'Moráin, C | 1 |
| van Zanten, SV | 1 |
| Louw, JA | 1 |
| Theodórs, A | 1 |
| Sundin, M | 2 |
| Friedman, LS | 1 |
| Christensen, E | 2 |
| Wiklund, IK | 1 |
| Janssens, J | 1 |
| Rácz, I | 1 |
| Sanduleanu, S | 1 |
| Stridsberg, M | 1 |
| Jonkers, D | 1 |
| Hameeteman, W | 1 |
| Biemond, I | 2 |
| Lundqvist, G | 1 |
| Lamers, C | 1 |
| Stockbrügger, RW | 1 |
| Liu, WZ | 1 |
| Shi, Y | 1 |
| Zhang, DZ | 1 |
| Xu, WW | 1 |
| Jones, R | 1 |
| Crouch, SL | 1 |
| Sato, K | 2 |
| Ohkura, R | 2 |
| Murai, T | 2 |
| Shimizu, H | 1 |
| Watanabe, S | 2 |
| Sato, N | 4 |
| Bergmann, JF | 1 |
| Goddard, AF | 1 |
| Logan, RP | 1 |
| Lawes, S | 1 |
| Spiller, RC | 2 |
| Catalano, F | 1 |
| Branciforte, G | 1 |
| Brogna, A | 1 |
| Bentivegna, C | 1 |
| Luca, S | 1 |
| Terranova, R | 1 |
| Michalos, A | 1 |
| Dawson, BK | 1 |
| Chodash, HB | 1 |
| Hamlet, A | 1 |
| Stage, L | 1 |
| Lönroth, H | 1 |
| Cahlin, C | 1 |
| Nyström, C | 1 |
| Pettersson, A | 1 |
| Moshkowitz, M | 1 |
| Brill, S | 1 |
| Konikoff, FM | 1 |
| Reif, S | 1 |
| Arber, N | 1 |
| Halpern, Z | 1 |
| Schubert, ML | 1 |
| Grimm, KJ | 1 |
| Farup, PG | 1 |
| Hovde, O | 1 |
| Torp, R | 1 |
| Ohlsson, L | 1 |
| Wahlqvist, P | 1 |
| Werdmuller, BF | 1 |
| van der Putten, AB | 1 |
| Veenendaal, RA | 1 |
| Balk, AG | 1 |
| Loffeld, RJ | 1 |
| Zwimpfer, J | 1 |
| Ballard, ED | 1 |
| Fennerty, MB | 2 |
| Hammett, DC | 1 |
| Evans, MF | 1 |
| Greenberg, PD | 1 |
| Cello, JP | 1 |
| Adamsson, I | 1 |
| Nord, CE | 1 |
| Lundquist, P | 1 |
| Sjöstedt, S | 1 |
| Edlund, C | 1 |
| Samoyeau, R | 2 |
| De Mascarel, A | 2 |
| Megraud, F | 4 |
| Mamun, M | 1 |
| Caddick, S | 1 |
| Siddiqi, MA | 1 |
| Lugannani, C | 1 |
| Strickland, C | 1 |
| Blondon, H | 1 |
| Aydin, A | 1 |
| Ersöz, G | 1 |
| Tekesin, O | 1 |
| Akçiçek, E | 1 |
| Tuncyürek, M | 1 |
| Dott, AG | 1 |
| Johnson, L | 1 |
| Szlachcic, A | 1 |
| Sliwowski, Z | 1 |
| Karczewska, E | 1 |
| Pytko-Polonczyk, J | 1 |
| Hirai, S | 1 |
| Nishira, T | 1 |
| Kikuchi, S | 1 |
| Takei, Y | 1 |
| Bojarski, C | 1 |
| Epple, HJ | 1 |
| Kirstein, FW | 1 |
| Fromm, M | 1 |
| Bisson, S | 1 |
| Riecken, EO | 1 |
| Schulzke, JD | 1 |
| Feltbower, R | 2 |
| Brown, J | 2 |
| Mason, S | 2 |
| Mason, J | 2 |
| Richards, ID | 1 |
| Dowell, AC | 1 |
| Wittayalertpanya, S | 1 |
| Wannachai, N | 1 |
| Thongnopnua, P | 1 |
| Mahachai, V | 1 |
| Testoni, PA | 1 |
| Bagnolo, F | 1 |
| Rune, S | 1 |
| Bonnevie, O | 1 |
| Breinstrup, H | 1 |
| Funch-Jensen, P | 1 |
| Matzen, P | 1 |
| Shuster, J | 1 |
| Lerro, P | 1 |
| Perrucci, V | 1 |
| Morra, I | 1 |
| Lombardo, L | 1 |
| Gaido, F | 1 |
| Ansaldi, N | 1 |
| Hsu, PI | 1 |
| Lai, KH | 1 |
| Tseng, HH | 1 |
| Lo, GH | 1 |
| Lo, CC | 1 |
| Lin, CK | 1 |
| Cheng, JS | 1 |
| Chan, HH | 1 |
| Ku, MK | 1 |
| Peng, NJ | 1 |
| Chien, EJ | 1 |
| Chen, W | 1 |
| Hsu, PN | 1 |
| Fakheri, H | 1 |
| Malekzadeh, R | 1 |
| Merat, S | 1 |
| Khatibian, M | 1 |
| Fazel, A | 1 |
| Alizadeh, BZ | 1 |
| Massarrat, S | 1 |
| Ohkusa, T | 1 |
| Fujiki, K | 1 |
| Takashimizu, I | 1 |
| Kumagai, J | 1 |
| Tanizawa, T | 1 |
| Eishi, Y | 1 |
| Yokoyama, T | 1 |
| Watanabe, M | 1 |
| Smout, AJ | 3 |
| Broutet, N | 1 |
| Marais, A | 1 |
| Salamon, R | 1 |
| Lin, Z | 1 |
| Chen, JD | 1 |
| Parolisi, S | 1 |
| Shifflett, J | 1 |
| McCallum, RW | 1 |
| Chuang, CH | 2 |
| Sheu, BS | 2 |
| Yang, HB | 2 |
| Wu, JJ | 2 |
| Lin, XZ | 1 |
| Della Libera, E | 1 |
| Rohr, MR | 1 |
| Moraes, M | 1 |
| Siqueira, ES | 1 |
| Ferrari, AP | 1 |
| Meier, R | 1 |
| Wettstein, A | 1 |
| Drewe, J | 1 |
| Geiser, HR | 1 |
| Luzza, F | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Trimboli, V | 1 |
| Pallone, F | 1 |
| Yamada, T | 2 |
| Hojo, M | 1 |
| Cook, KF | 1 |
| Wray, NP | 1 |
| Lewin van den Broek, NT | 1 |
| Numans, ME | 1 |
| Buskens, E | 1 |
| Verheij, TJ | 1 |
| de Wit, NJ | 1 |
| Froehlich, F | 1 |
| Gonvers, JJ | 1 |
| Wietlisbach, V | 1 |
| Burnand, B | 1 |
| Hildebrand, P | 1 |
| Schneider, C | 1 |
| Saraga, E | 1 |
| Beglinger, C | 1 |
| Vader, JP | 1 |
| Stanghellini, V | 1 |
| Galmiche, JP | 1 |
| Fendrick, AM | 1 |
| Tankovic, J | 1 |
| Lamarque, D | 1 |
| Lascols, C | 1 |
| Soussy, CJ | 1 |
| Laurent, J | 1 |
| Fléjou, JF | 1 |
| Caekaert, A | 1 |
| Kearney, DJ | 1 |
| Matheson, AJ | 1 |
| Jarvis, B | 1 |
| Misawa, H | 1 |
| Ohtaka, K | 1 |
| Schwartz, MP | 1 |
| Samsom, M | 1 |
| Van Berge Henegouwen, GP | 1 |
| Wang, YL | 1 |
| Huang, AH | 1 |
| Schilling, D | 1 |
| Messerer, P | 1 |
| Ott, MG | 1 |
| Schauwecker, P | 1 |
| Zober, A | 1 |
| Riemann, JF | 1 |
| Bazzoli, F | 1 |
| Zagari, RM | 1 |
| Pozzato, P | 1 |
| Fossi, S | 1 |
| Ricciardiello, L | 1 |
| Nicolini, G | 1 |
| De Luca, L | 1 |
| Berretti, D | 1 |
| Alampi, G | 1 |
| Di Pietro, C | 1 |
| Morelli, P | 1 |
| Roda, E | 1 |
| Choi, IJ | 1 |
| Choi, KW | 1 |
| Kim, JH | 1 |
| Ahn, DS | 1 |
| Yang, US | 1 |
| Rew, JS | 1 |
| Lee, SI | 1 |
| Rhee, JC | 1 |
| Chung, IS | 1 |
| Chung, JM | 1 |
| Hong, WS | 1 |
| Georgopoulos, SD | 1 |
| Ladas, SD | 1 |
| Karatapanis, S | 1 |
| Triantafyllou, K | 1 |
| Spiliadi, C | 1 |
| Mentis, A | 1 |
| Artikis, V | 1 |
| Raptis, SA | 1 |
| Duffett, S | 1 |
| Drummond, M | 1 |
| Crocombe, W | 1 |
| Bown, RL | 1 |
| Axon, A | 1 |
| Van Zanten, SJ | 1 |
| Ferguson, RA | 1 |
| Tanaka, A | 1 |
| Chayama, K | 1 |
| Kitadai, Y | 1 |
| Kawamura, Y | 1 |
| Wermeille, J | 1 |
| Cunningham, M | 1 |
| Dederding, JP | 1 |
| Girard, L | 1 |
| Baumann, R | 1 |
| Zelger, G | 1 |
| Buri, P | 1 |
| Metry, JM | 1 |
| Sitavanc, R | 1 |
| Gallaz, L | 1 |
| Merki, H | 1 |
| Godin, N | 1 |
| Dhir, V | 1 |
| Gené, E | 1 |
| Azagra, R | 1 |
| López, T | 1 |
| Cubells, MJ | 1 |
| Ivanova, NG | 1 |
| Knippig, C | 1 |
| Arand, F | 1 |
| Nilius, M | 1 |
| Bayerdörffer, E | 1 |
| Klein, U | 1 |
| Halabi, A | 1 |
| Kirch, W | 1 |
| Gyenes, E | 1 |
| Burridge, SM | 1 |
| Spencer, G | 1 |
| Bolton, G | 1 |
| Purser, K | 1 |
| Brooks, S | 1 |
| Prosser, S | 1 |
| Harrison, G | 1 |
| Gant, PW | 1 |
| Baak, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia: A Randomized Comparison of Different Prescribing Behaviors[NCT01851863] | Phase 4 | 262 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes[NCT05449028] | 230 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Study of Gastroscopy Negative Dyspepsia - Effect of Acid-reducing Treatment and Information on Various Types of Dysmotility.[NCT00437346] | 35 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to The project leader left our hospital and the project were shut down.) | |||
| High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment[NCT00132171] | Phase 3 | 1,000 participants | Interventional | 2001-01-31 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia[NCT00547703] | 5 participants (Actual) | Interventional | 2008-02-29 | Terminated (stopped due to Not enough participants - only 5 since the study started) | |||
| Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study[NCT02476097] | Phase 4 | 58 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing[NCT00778193] | Phase 4 | 125 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Evaluation of Esophageal and Gastric Acid Levels in Patients Presenting With Upper Gastrointestinal Symptoms Using a Novel PH System[NCT00579410] | 85 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
The severity of patients' dyspeptic symptoms were assessed using the Leeds Dyspepsia Questionnaire (LDQ) at week 0 and 8. The LDQ contains eight items about epigastric pain, retro-sternal pain, regurgitation, nausea, vomiting, belching, early satiety and dysphagia with six grades for each item and a sum of the eight symptom scores make the LDQ score.LDQ scores of 0 - 4 were classified as very mild dyspepsia, 4 - 8 as mild dyspepsia, 9 -15 as moderate dyspepsia, and > 15 as severe or very severe dyspepsia. The change of LDQ scores was calculated by LDQ scores of 8 weeks minus baseline, with lower values represent a better outcome. (NCT01851863)
Timeframe: week 0 and 8
| Intervention | units on LDQ scale (Mean) |
|---|---|
| Deanxit(Psychological and GI) + Omeprazole | -3.85 |
| Deanxit(Psychological) + Omeprazole | -2.51 |
| Deanxit(Without Explanation) + Omeprazole | -2.49 |
| Proton Pump Inhibitor | -1.31 |
The patients were asked to keep a diary to record their medication intake. At each visit (weeks 1, 2, 4, 8), the patient bring back the drug bottle and the diary, then the physician recorded the number of pills remaining in the bottle. Pills remained more than 20% at any visit or seven days of consecutive abstinence were adopted as the criterion for identifying therapy noncompliance. (NCT01851863)
Timeframe: weeks 1, 2, 4, 8
| Intervention | participants (Number) |
|---|---|
| Deanxit(Psychological and GI) + Omeprazole | 44 |
| Deanxit(Psychological) + Omeprazole | 28 |
| Deanxit(Without Explanation) + Omeprazole | 31 |
Number of participants with adverse reactions were recorded to analyze the safety profile of treatment. (NCT01851863)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| Deanxit(Psychological and GI) + Omeprazole | 6 |
| Deanxit(Psychological) + Omeprazole | 9 |
| Deanxit(Without Explanation) + Omeprazole | 5 |
| Proton Pump Inhibitor | 2 |
Each patient was surveyed using the Hospital Anxiety and Depression Scale to assess the psychiatric symptom at week 0 and 8.The HADS consists of 14 items, seven of which assess anxiety, and seven assess depression. The anxiety and depression subscales were calculated independently. The patients were asked to answer each item on a four-point (0 - 3) scale. Scores of 0 to 7 on either subscale can be regarded as within the normal range, scores of 8 to 10 are suggestive of the presence of the respective state, and scores of 11 or higher indicate the probable presence of the respective mood disorder. The change of HADS scores was calculated by HADS anxiety and depression scores of 8 weeks minus baseline, with lower values indicate better outcome. (NCT01851863)
Timeframe: week 0 and 8
| Intervention | units on HADS score (Mean) | |
|---|---|---|
| HADS anxiety score | HADS depression score | |
| Deanxit(Psychological and GI) + Omeprazole | -4.46 | -4.82 |
| Deanxit(Psychological) + Omeprazole | -2.29 | -2.25 |
| Deanxit(Without Explanation) + Omeprazole | -2.78 | -2.86 |
| Proton Pump Inhibitor | -1.68 | -1.88 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
Patient would answer yes or no to a simple question asking whether they had adequate relief of abdominal pain or discomfort. This was measured at weeks 2,4 and 8 of the study but only week 8 was reported. What is being reported is the number of participants who answered yes. (NCT00547703)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| Nortriptyline | 2 |
| Placebo | 1 |
27 reviews available for omeprazole and Indigestion
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Toxic epidermal necrolysis and neutropaenia: complications of omeprazole.
Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Combined Modality Therapy; Diabetes Mellitus, Type 1; Di | 2009 |
What's new: proton pump inhibitors and pediatrics.
Topics: Child; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Ome | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Epigastric pain in dyspepsia and reflux disease.
Topics: Abdominal Pain; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Gastroesophageal Reflux; He | 2003 |
The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Humans; Omeprazole; Peptic Ul | 2003 |
Cost-effectiveness of a 'score and scope' strategy for the management of dyspepsia.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cost-Benefit Analysis; Decision Trees; Diagn | 2005 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
[Functional dyspepsia: approaches to Helicobacter pylori eradication therapy].
Topics: Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Gastritis | 1995 |
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicoba | 1993 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; | 1996 |
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; H | 1996 |
The changing role of H2-receptor antagonists in acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1996 |
Healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions, and relief of dyspeptic symptoms: a commentary on the new data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Dyspepsia; Humans; Misoprostol; Omeprazo | 1998 |
Eradication therapies for Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combi | 1998 |
[25 years of gastric acid blockers].
Topics: Anti-Ulcer Agents; Cimetidine; Dyspepsia; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1999 |
Review article: tackling the "dyspeptic problem".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dyspepsia; Helicobacter pylori; Humans; | 2001 |
Review article: managing the dyspeptic patient--an interactive discussion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2001 |
Lansoprazole: an update of its place in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind M | 2002 |
The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Humans; Male; Omeprazole; Randomiz | 2002 |
Approaches to uninvestigated dyspepsia.
Topics: Anti-Ulcer Agents; Dyspepsia; Humans; Omeprazole; Primary Health Care | 2002 |
Use of antisecretory agents as a trial of therapy.
Topics: Anti-Ulcer Agents; Dyspepsia; Gastroesophageal Reflux; Humans; Omeprazole | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpe | 2002 |
[Non-ulcer dyspepsia and H. pylori].
Topics: Amoxicillin; Clarithromycin; Dyspepsia; Gastric Acid; Gastric Emptying; Helicobacter Infections; Hel | 2002 |
[Drug therapy of non-ulcer dyspepsia].
Topics: Antacids; Bismuth; Dyspepsia; Histamine H2 Antagonists; Humans; Omeprazole; Pirenzepine; Sucralfate | 1991 |
174 trials available for omeprazole and Indigestion
| Article | Year |
|---|---|
Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
Topics: Curcuma; Curcumin; Double-Blind Method; Dyspepsia; Humans; Omeprazole; Pain; Quality of Life; Treatm | 2022 |
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Topics: Abdominal Pain; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagitis; Heartburn; Humans; O | 2023 |
Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial.
Topics: Adult; Curcumin; Dyspepsia; Female; Humans; Middle Aged; Omeprazole; Pain; Proton Pump Inhibitors | 2023 |
Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Apoptosis; Caspase 3; Clarithromycin; Dietary Fats, | 2017 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochr | 2014 |
Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; | 2014 |
Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients.
Topics: Adult; Aged; Anthracenes; Attitude of Health Personnel; China; Communication; Drug Combinations; Dys | 2015 |
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug The | 2015 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, | 2016 |
The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Double-Blind Method; | 2009 |
[Clinical observation on transcutaneous electrical acupoint stimulation for treatment of functional dyspepsia].
Topics: Acupuncture Points; Adult; Aged; Benzamides; Domperidone; Dyspepsia; Female; Gastrointestinal Agents | 2009 |
[Effectiveness of Ultop 10 mg using at treatment of functional (nonulcer) dyspepsia syndrome].
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Female; Humans; Male; Middle Aged; Omeprazole; Syndrome | 2009 |
Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse.
Topics: Adult; Aged; Dyspepsia; Endoscopy, Gastrointestinal; Female; Heart Neoplasms; Humans; Male; Middle A | 2010 |
Helicobacter pylori eradication in functional dyspepsia: HEROES trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind M | 2011 |
Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).
Topics: Algorithms; Benzamides; Diterpenes; Dose-Response Relationship, Drug; Dyspepsia; Famotidine; Gastroe | 2012 |
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dicl | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Chronic Disease; Drug T | 2002 |
Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combi | 2002 |
Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients.
Topics: Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2002 |
Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Dyspeps | 2003 |
A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia.
Topics: Administration, Oral; Double-Blind Method; Dyspepsia; Endoscopy; Enzyme Inhibitors; Female; Follow-U | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Humans; Hydrogen-Ion Concent | 2002 |
Impact of upper endoscopy on satisfaction in patients with previously uninvestigated dyspepsia.
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up St | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Breath Tests; Dose-Response Relations | 2003 |
Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Double-Blind | 2003 |
Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; H | 2003 |
Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Health Status; Heartburn; He | 2003 |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2003 |
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Benzi | 2003 |
Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Te | 2003 |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2003 |
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Dose-Response Relations | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; B | 2003 |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bac | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamase Inhibitors; beta-Lactamases; Clarithro | 2004 |
[Efficacy of Helicobacter pylori eradication in non-ulcer dyspepsia].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2004 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithrom | 2004 |
Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost Savings; Cost-Ben | 2003 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benz | 2004 |
Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal | 2004 |
Empirical treatment followed by a test-and-treat strategy is more cost-effective in comparison with prompt endoscopy or radiography in patients with dyspeptic symptoms: a randomized trial in a primary care setting.
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylo | 2004 |
Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2004 |
Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption.
Topics: Adult; Aged; Delivery of Health Care; Denmark; Dose-Response Relationship, Drug; Drug Administration | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design.
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Humans; Male; Middle Aged; Omeprazole; Re | 2004 |
Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Gastric Acid; Gastroesophageal Reflux; Hu | 2004 |
A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea.
Topics: Adult; Case-Control Studies; Double-Blind Method; Duodenum; Dyspepsia; Female; Follow-Up Studies; Ga | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Classification of dyspepsia and response to treatment with proton-pump inhibitors.
Topics: Anti-Ulcer Agents; Dyspepsia; Humans; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2004 |
A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia.
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagus; Female; Humans; Hydrogen-Ion Concentra | 2005 |
Eradication rate of Helicobacter pylori in dyspeptic patients.
Topics: Analysis of Variance; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Drug Therapy, Combination; | 2005 |
[Effect of the Helicobacter pylori eradication in patients with functional dyspepsia: randomised placebo-controlled trial].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Confidence Intervals; | 2005 |
Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Drug Administrat | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2005 |
A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study.
Topics: Adult; Aged; Cisapride; Cost-Benefit Analysis; Drug Costs; Dyspepsia; Female; Gastrointestinal Agent | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2006 |
Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clar | 2006 |
Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Denmark; Drug Therapy, Combinat | 2006 |
Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Dyspepsia; Enzyme Inhibitors; Female; Gastr | 2006 |
Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: a randomized trial in primary care.
Topics: Adult; Anti-Ulcer Agents; Cost-Benefit Analysis; Dyspepsia; Endoscopy, Gastrointestinal; Female; Hel | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; | 2006 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Hu | 2007 |
Cost-effectiveness analysis of two management strategies for dyspepsia.
Topics: Age Factors; Cost-Benefit Analysis; Dyspepsia; Female; Gastroscopy; Humans; Male; Middle Aged; Omepr | 2007 |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use.
Topics: Adult; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Ana | 2007 |
Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Dy | 2008 |
Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Community Health Services; Cost-Benefit Analy | 2008 |
Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model.
Topics: Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ad | 2008 |
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Famotidine; F | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endosco | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication.
Topics: Adult; Age Factors; Amoxicillin; Chronic Disease; Drug Therapy, Combination; Dyspepsia; Female; Gast | 1994 |
One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Clinical Trials as Topic; Drug Therapy, Combination; | 1994 |
Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Topics: Adult; Cimetidine; Drug Hypersensitivity; Dyspepsia; Famotidine; Female; Histamine; Histamine H2 Ant | 1993 |
[Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?].
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Helico | 1994 |
Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 1995 |
Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Duodenal Ulcer; Dy | 1996 |
A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, C | 1996 |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 1996 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Th | 1995 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Dyspep | 1996 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 1997 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
[Endocrine and exocrine gastric mucosal secretion in the course of H. pylori eradication in patients with non-ulcer dyspepsia].
Topics: Amoxicillin; Bismuth; Dyspepsia; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; H | 1997 |
One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagoscopy; Female; Gastroesophageal Reflux; H | 1998 |
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected].
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Alginates; Anti-Ulcer Agents; Biocompati | 1998 |
Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Does endoscopy have a positive impact on quality of life in dyspepsia?
Topics: Abdominal Pain; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer A | 1998 |
Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsi | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 1998 |
First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice.
Topics: Adult; Aged; Aged, 80 and over; Alginates; Antacids; Anti-Ulcer Agents; Dyspepsia; Family Practice; | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Cl | 1998 |
A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspe | 1998 |
Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).
Topics: Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; | 1998 |
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doub | 1998 |
Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis.
Topics: Adult; Cost-Benefit Analysis; Dyspepsia; Endoscopy; Female; Helicobacter Infections; Humans; Male; M | 1998 |
Classification of dyspepsia. Identification of independent symptom components in 7270 consecutive, unselected dyspepsia patients from general practice.
Topics: Adult; Clinical Trials as Topic; Dyspepsia; Female; Gastrointestinal Agents; Humans; Male; Middle Ag | 1998 |
Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia.
Topics: Analysis of Variance; Diet Records; Double-Blind Method; Dyspepsia; Enzyme Inhibitors; Female; Human | 1998 |
Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; D | 1999 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 1999 |
Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
[Eradication of Helicobacter pylori does not significantly improve dyspepsia].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Gastric Mucosa; Helicobacter pylori; Humans; Mu | 1999 |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspeps | 1999 |
Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.
Topics: Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; D | 1999 |
A novel tablet-based 13C urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy.
Topics: Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Dyspepsia; Female; Helicobacter Infections; Helico | 1999 |
The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithr | 1999 |
H. pylori and nonulcer dyspepsia: not guilty as charged.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dyspepsi | 1999 |
Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Gastroesophageal Reflux; Hel | 1999 |
Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study.
Topics: Absenteeism; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Animals; Anti-Ulcer Agents | 1999 |
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Cla | 1999 |
Functional (non-ulcer) dyspepsia and Helicobacter pylori infection. To treat or not to treat?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 1999 |
Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia.
Topics: Adult; Antibodies, Bacterial; Blotting, Western; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter | 1999 |
Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 1999 |
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
Garlic oil and Helicobacter pylori infection.
Topics: Adult; Allyl Compounds; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disulfides; Dyspe | 2000 |
Helicobacter pylori and its eradication in rosacea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2000 |
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose- | 2000 |
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Topics: Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 2000 |
Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia.
Topics: Adult; Amoxicillin; Drug Interactions; Dyspepsia; Enzyme Inhibitors; Female; Gastric Mucosa; Helicob | 2000 |
Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.
Topics: Adolescent; Adult; Aged; Algorithms; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Foll | 2000 |
In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern.
Topics: Administration, Oral; Adult; Analysis of Variance; Biopsy, Needle; Breath Tests; Clarithromycin; Dru | 2000 |
Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Denmark; Dyspepsia; Female; Humans; Male; Middle Aged; O | 2000 |
Identifying responders to acid suppression in dyspepsia using a random starting day trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Dyspepsia; Female; Gastroesophageal Re | 2000 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Clarithr | 2001 |
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia.
Topics: Adult; Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Co | 2001 |
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duoden | 2001 |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benz | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Health Status; Humans; Male; | 2001 |
A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.
Topics: Anti-Ulcer Agents; Cimetidine; Cisapride; Clinical Protocols; Dyspepsia; Endoscopy, Gastrointestinal | 2001 |
Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absenteeism; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: Administration, Oral; Adult; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azit | 2001 |
Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combinatio | 2001 |
Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Chemoreceptor Cel | 2001 |
Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with nonulcer dyspepsia.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Dyspepsia; Female; Helicobacter Infections; Helicobacter pyl | 2001 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2002 |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 2002 |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions | 2002 |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Dyspepsia; Female; Health Care | 2002 |
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Canada; Clarithromy | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Benzimidazoles; Dyspepsia; Enzyme Inhibi | 2002 |
Cardiovascular effects of omeprazole and famotidine.
Topics: Aged; Cardiac Output; Double-Blind Method; Dyspepsia; Famotidine; Female; Heart Failure; Hemodynamic | 1992 |
Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori.
Topics: Amoxicillin; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, C | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Dr | 1992 |
Repeated intravenous bolus injections of omeprazole: effects on 24-hour intragastric pH, serum gastrin, and serum pepsinogen A and C.
Topics: Adult; Drug Administration Schedule; Dyspepsia; Female; Gastric Acidity Determination; Gastrins; Hum | 1991 |
101 other studies available for omeprazole and Indigestion
| Article | Year |
|---|---|
[Helicobacter pylori infection in the HIV + population: a comorbidity to think about].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Ulcer Agents; Clarithromycin; Comor | 2020 |
Giardia intestinalis in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Antiprotozoal Agents; Drug Therapy, Combination; Duodenum; Dyspepsia; Enzyme-Link | 2013 |
Incidence of postoperative dyspepsia is not associated with prophylactic use of drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia Recovery Period; Anesthesia, General; Dyspeps | 2014 |
Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacteroidetes; Dyspepsia; Female; Firmicutes; Gastric | 2016 |
Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia.
Topics: Adult; Aged; Amoxicillin; Brazil; Clarithromycin; Cytochrome P-450 CYP2C19; Dyspepsia; Endoscopy, Ga | 2016 |
A search for Helicobacter pyloriin localized vulvodynia.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Dysp | 2008 |
I was recently diagnosed with "dyspepesia." Is this a fancy term for heartburn? Are there other ways of preventing and easing symptoms besides yoga classes to reduce stress and Prilosec for reflux?
Topics: Diet; Dyspepsia; Enzyme Inhibitors; Gastroesophageal Reflux; Helicobacter pylori; Humans; Omeprazole | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat.
Topics: Drug Administration Schedule; Dyspepsia; Evidence-Based Medicine; Gastric Acid; Gastric Mucosa; Gast | 2009 |
Inappropriate use of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cross-Sectional Studies; Dyspepsia | 2010 |
Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.
Topics: Anti-Bacterial Agents; Case-Control Studies; Clarithromycin; Drug Resistance, Microbial; Dyspepsia; | 2010 |
Editorial: just how "difficult" is it to withdraw PPI treatment?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophagitis; Gastric Acid; Gastroesophageal Refl | 2010 |
A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.
Topics: Anti-Ulcer Agents; Canada; Cost of Illness; Cost-Benefit Analysis; Disease Management; Dyspepsia; En | 2010 |
A case of gastric polyposis in antral area of stomach following prolonged proton-pump therapy.
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Humans; Male; Omeprazole; Polyps; Proton Pump Inhibitors; Stoma | 2010 |
Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area.
Topics: Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resis | 2010 |
It is difficult to discontinue PPI treatment in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Esophagitis; Gastric A | 2011 |
Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Administration Schedul | 2011 |
Cure of alopecia areata after eradication of Helicobacter pylori: a new association?
Topics: Adult; Alopecia Areata; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dyspepsia; | 2011 |
[Adverse events associated with long-term use of proton pump inhibitors].
Topics: Anti-Ulcer Agents; Bacterial Infections; Congenital Abnormalities; Dyspepsia; Fractures, Bone; Gastr | 2012 |
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Canad | 2002 |
Functional dyspepsia: bye-bye to PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; China; Dyspepsia; Gastroesophageal R | 2002 |
Quantification of Helicobacter pylori resistance in functional and organic dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cohort Studies; Drug | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
[Long-term course of reflux symptoms following Helicobacter pylori eradication].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 2004 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2004 |
Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001.
Topics: Adult; Age Factors; Amoxicillin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combinati | 2004 |
Early epigastric pain after PPI administration: exacerbation of Helicobacter pylori corpus gastritis?
Topics: Abdominal Pain; Anti-Ulcer Agents; Dyspepsia; Gastritis; Gastroesophageal Reflux; Helicobacter Infec | 2004 |
Treat the patients' main dyspepsia complaint, not the ROME criteria.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Enzyme Inhibitors; Family | 2004 |
Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of Helicobacter pylori infections?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Biopsy; C-Reactive Protein; Calcitonin; | 2004 |
[Prevention of ulcer lesions under non-steroid antirheumatic agents. For each patient the appropriate stomach protection].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase Inhibitors; Dyspepsia; Hi | 2004 |
[The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
The use of subcutaneous omeprazole in the treatment of dyspepsia in palliative care patients.
Topics: Abdominal Pain; Aged; Anti-Ulcer Agents; Dyspepsia; Enzyme Inhibitors; Female; Humans; Injections, S | 2004 |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Asian People; Clarithromycin; Drug Resistan | 2005 |
Validation of the Reflux Disease Questionnaire for a German population.
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Cultural Comparison; Dyspepsia; Female; Gastroesophageal Reflu | 2005 |
Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
Rabeprazole-induced acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Acute Kidney Injury; Anti-Ulcer Agents; Benz | 2005 |
Helicobacter pylori status and symptom assessment two years after eradication in pediatric patients from a high prevalence area.
Topics: Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; | 2005 |
Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura.
Topics: Amoxicillin; Breath Tests; Clarithromycin; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infect | 2005 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dyspepsia; Female; Humans; Male; Midd | 2006 |
Helicobacter pylori eradication in peptic dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration | 2005 |
Proton pump inhibitors and acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Kidney Injury; Adult; Age Distribution; Aged; Aged, 8 | 2006 |
Management of the dyspeptic patient: anything goes?
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Denmark; Drug Therapy, Combinat | 2006 |
The management of upper gastrointestinal symptoms: is endoscopy indicated?
Topics: Age Factors; Antacids; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Gastroesophageal R | 2007 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
I was recently diagnosed with "dyspepsia". Is this just a fancy term for heartburn? Are there other ways of preventing and easing symptoms besides yoga classes to reduce stress and Prilosec for reflux?
Topics: Anti-Ulcer Agents; Dyspepsia; Gastroesophageal Reflux; Humans; Meditation; Omeprazole; Stress, Physi | 2007 |
A comparison of community pharmacists' views of over-the-counter omeprazole and simvastatin.
Topics: Anticholesteremic Agents; Attitude of Health Personnel; Community Pharmacy Services; Dyspepsia; Huma | 2007 |
[Evidence based treatment strategy for dyspeptic symptoms].
Topics: Dyspepsia; Evidence-Based Medicine; Gastritis; Histamine H2 Antagonists; Humans; Omeprazole; Proton | 2007 |
Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
Topics: Adverse Drug Reaction Reporting Systems; Cohort Studies; Diarrhea; Drug Monitoring; Dyspepsia; Engla | 2008 |
[Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1995 |
Prescribing of antacids and ulcer-healing drugs in primary care in the north of England.
Topics: Adolescent; Adult; Age Distribution; Aged; Antacids; Child; Child, Preschool; Drug Prescriptions; Dr | 1995 |
Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication.
Topics: Adult; Aged; Amoxicillin; Breath Tests; Carbon Isotopes; Drug Therapy, Combination; Dyspepsia; Esoph | 1994 |
[Azithromycin-omeprazole. Treatment for the eradication of Helicobacter pylori].
Topics: Adult; Aged; Azithromycin; Drug Evaluation; Drug Therapy, Combination; Dyspepsia; Female; Helicobact | 1994 |
Azithromycin for the cure of Helicobacter pylori infection.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combina | 1996 |
General practitioners' approach to dyspepsia. Survey of consultation frequencies, treatment, and investigations.
Topics: Adolescent; Adult; Age Factors; Cross-Sectional Studies; Dyspepsia; Endoscopy, Digestive System; Fem | 1996 |
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer | 1996 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1996 |
Evaluation of the dyspeptic patient: a cost-utility study.
Topics: Adult; Ambulatory Care; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, | 1997 |
Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; D | 1997 |
One-day high-dose combined therapy of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Evaluation; Drug Therapy, Combination; | 1997 |
Management in general practice of patients with persistent dyspepsia. A decision analysis.
Topics: Decision Trees; Disease Management; Dyspepsia; Endoscopy; Gastroenterology; Humans; Omeprazole; Trea | 1997 |
Does Helicobacter pylori infection affect gastric emptying in patients with functional dyspepsia?
Topics: Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Dyspepsia; Female; Gastric Empty | 1997 |
Weekend therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sc | 1998 |
Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
[Is dental plaque a normal Helicobacter pylori reservoir?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Benzimidazoles; Clari | 1998 |
Pyrexia, anaemia and acute renal failure secondary to omeprazole.
Topics: Acute Kidney Injury; Aged; Anemia; Anti-Inflammatory Agents; Anti-Ulcer Agents; Blood Sedimentation; | 1998 |
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Esophagitis, Peptic; Gastric Acidity Dete | 1998 |
Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test.
Topics: Anti-Ulcer Agents; Antigens, Bacterial; Breath Tests; Dyspepsia; False Negative Reactions; False Pos | 1998 |
Helicobacter pylori and nonulcer dyspepsia.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastroint | 1998 |
Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Topics: Adult; Aged; Anti-Ulcer Agents; Case-Control Studies; Chromogranin A; Chromogranins; Cross-Sectional | 1999 |
Treatment of Helicobacter pylori infection in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1999 |
Functional dyspepsia has a good prognosis irrespective of H. pylori status. Long-term follow-up of symptoms after anti H. pylori treatment.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia | 1999 |
[Symptomatic improvement of patients with nonulcer dyspepsia after Helicobacter pylori eradication].
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Dyspepsia; Helicobacter Inf | 1999 |
Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Omeprazole and excessive sweating, if unrecognised, may lead to unnecessary investigations.
Topics: Anti-Ulcer Agents; Dyspepsia; Humans; Hyperhidrosis; Male; Middle Aged; Omeprazole; Proton Pump Inhi | 1999 |
Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients?
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Dyspepsi | 1999 |
[Eradication of Helicobacter pylori: what is the effect on symptoms of non-ulcerous dyspepsia?].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Female; Helicobact | 1999 |
Rational prescribing: practice audit and drug switch in dyspepsia management.
Topics: Cost Savings; Dyspepsia; Family Practice; Histamine H2 Antagonists; Humans; Medical Audit; Omeprazol | 1999 |
No H pylori: less dyspepsia?
Topics: Anti-Ulcer Agents; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Rese | 2000 |
Omeprazole and nephritis.
Topics: Acute Kidney Injury; Aged; Anti-Ulcer Agents; Dyspepsia; Female; Humans; Nephritis, Interstitial; Om | 2000 |
CagA seropositivity and the severity of Helicobacter pylori infection in dyspeptic children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Bacterial | 2000 |
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2001 |
Dyspepsia responsive to acid suppression therapy: reflux disease or duodenal hypersensitivity?
Topics: Antacids; Duodenum; Dyspepsia; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Huma | 2000 |
Prevalence of gastric myoelectrical abnormalities in patients with nonulcer dyspepsia and H. pylori infection: resolution after H. pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Electromyography; | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Br | 2001 |
Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; DNA, Bacterial; Dru | 2001 |
Key topics in Helicobacter pylori eradication in the management of the dyspeptic patient: a panel discussion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Heli | 2001 |
Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infecti | 2001 |
The role of treatment with proton pump inhibitors and anti-Helicobacter therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Helicob | 2001 |
Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 | 2001 |
[Dyspepsia and Helicobacter pylori infection in employees of a large industry. Results of a prospective BASF Helicobacter pylori prevention campaign].
Topics: Adolescent; Adult; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Germany; | 2002 |
pH-Hp: implications for dyspepsia management.
Topics: Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Omepraz | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2002 |
[Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Drug | 2002 |
Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Child; Child, Preschool; Clarithromycin; D | 2002 |